SNDL Weighs Direct Ownership Of Parallel's Medical Cannabis Arm After Lifting Stake To About 92%

CEO Zach George says the company will not wait on Washington and wants Parallel's medical business in its recurring earnings.

Share
SNDL Weighs Direct Ownership Of Parallel's Medical Cannabis Arm After Lifting Stake To About 92%

SNDL is looking at ways to own and consolidate Parallel's medical cannabis business directly, CEO Zach George said on the company's third-quarter earnings call on Tuesday. "We're not gonna wait for US government action to focus on the controllables," he told an analyst from Alliance Global Partners.

Medical first, recreational later

George said SNDL is "evaluating different paths to direct ownership and the financial consolidation of Parallel's medical cannabis business," citing its scale, an attractive margin profile and room for growth. He said more detail will come as the path and timing become clearer.

Asked how SNDL could put more capital into the U.S., he said it can already do so through its Sunstream joint venture, which has given it direct credit exposure and indirect equity exposure. Most of that capital has been repatriated, he said, and the next step is to reconcile the remaining exposures and work with regulators and exchanges to bring at least the medical exposure into its recurring profit and loss.

He pointed to other deals in which recreational assets were ring-fenced and held indirectly to support an up-listing. Given the lack of clarity on "schedule three for rec" in the U.S., he said, that approach would be part of the picture.

From 67% to 92% of Parallel

Parallel's restructuring finished in July. SNDL's participation in the rights offering lifted its indirect equity ownership from about 67% to about 92%, George said. Sunstream also bought more of Parallel's take-back debt at 75% of face value, raising its holding from 39.4% to 69.4%.

Parallel operates in Florida, Texas and Massachusetts, with 56 retail locations, three manufacturing and cultivation sites, about 800 employees and roughly US$150 million in net revenue, George said. SNDL also funded a new cultivation facility in Gainesville, Florida.

Chief Financial Officer Alberto Paredero said the quarter's $50.7 million drop in cash and equivalents mainly reflected $60.8 million of capital contributions to equity-accounted investees and $10 million of share repurchases.

A weak cannabis unit, record free cash flow

The quarter's net revenue was $238 million, down 2.5% from a year earlier. Operating loss was $48.3 million after a $52 million non-cash goodwill impairment tied to cannabis operations. Adjusted operating income was $5.2 million, up $14.8 million, and free cash flow hit a record $20 million.

Cannabis operations revenue fell 27.7% to $27.0 million after SNDL exited domestic dried flower. The company cut more than 30% of the workforce at its Kelowna site and has started a strategic review that could include asset sales.

SNDL bought back 5.4 million shares for $10 million in the quarter and plans a possible issuer bid of up to $50 million at no more than US$1.35 a share. It also expects a deal with Ontario's gaming regulator that would deconsolidate its Ontario franchise operations.

The Ontario deal, if completed, would cut reported net revenue by about $105 million on a trailing 12-month basis, while operating income would fall by only about $2 million.

Sources

More on SNDL

All SNDL (SNDL) coverage →